Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital.
Mallinckrodt Pharmaceuticals, Health Economics and Outcomes Research Department, Bedminster.
J Patient Saf. 2021 Mar 1;17(2):e76-e83. doi: 10.1097/PTS.0000000000000566.
Opioid analgesics are a mainstay for acute pain management, but postoperative opioid administration has risks. We examined the prevalence, risk factors, and consequences of opioid-related adverse drug events (ORADEs) in a previously opioid-free surgical population.
A retrospective, observational, cohort study using administrative, billing, clinical, and medication administration data from two hospitals. Data were collected for all adult patients who were opioid-free at admission, underwent surgery between October 1, 2015, and September 30, 2016, and received postoperative opioids. Potential ORADEs were determined based on inpatient billing codes or postoperative administration of naloxone. We determined independent predictors of ORADE development using multivariable logistic regression. We measured adjusted inpatient mortality, hospital costs, length of hospital stay, discharge destination, and readmission within 30 days for patients with and without ORADEs.
Among 13,389 hospitalizations where opioid-free patients had a single qualifying surgery, 12,218 (91%) received postoperative opioids and comprised the study cohort. Of these, we identified 1111 (9.1%) with a potential ORADE. Independent predictors of ORADEs included older age, several markers of disease severity, longer surgeries, and concurrent benzodiazepine use. Opioid-related adverse drug events were strongly associated with the route and duration of opioids administered postoperatively: 18% increased odds per day on intravenous opioids. In analyses adjusted for several covariates, presence of an ORADE was associated with 32% higher costs of hospitalization, 45% longer postoperative length of stay, 36% lower odds of discharge home, and 2.2 times the odds of death.
We demonstrate a high rate and severe consequences of potential ORADEs in previously opioid-free patients receiving postoperative opioids. Knowledge of risk factors and predictors of ORADEs can help develop targeted interventions to minimize the development of these potentially dangerous and costly events.
阿片类镇痛药是急性疼痛管理的主要药物,但术后阿片类药物的使用存在风险。我们研究了先前无阿片类药物使用史的手术患者中阿片类药物相关不良药物事件(ORADE)的发生率、风险因素和后果。
这是一项回顾性、观察性队列研究,使用了来自两家医院的行政、计费、临床和药物管理数据。数据收集了所有入院时无阿片类药物使用史、在 2015 年 10 月 1 日至 2016 年 9 月 30 日期间接受手术且术后使用阿片类药物的成年患者。根据住院计费代码或术后纳洛酮的使用确定潜在的 ORADE。我们使用多变量逻辑回归确定 ORADE 发生的独立预测因素。我们测量了有无 ORADE 患者的调整后住院死亡率、医院费用、住院时间、出院去向和 30 天内再入院率。
在 13389 例入院时无阿片类药物使用且进行单一符合条件手术的住院患者中,有 12218 例(91%)接受了术后阿片类药物治疗,构成了研究队列。在这些患者中,我们发现有 1111 例(9.1%)存在潜在的 ORADE。ORADE 的独立预测因素包括年龄较大、几种疾病严重程度标志物、手术时间较长以及同时使用苯二氮䓬类药物。阿片类药物相关不良药物事件与术后给予的阿片类药物途径和持续时间密切相关:静脉给予阿片类药物的天数每增加一天,发生 ORADE 的几率增加 18%。在调整了几个协变量的分析中,存在 ORADE 与住院费用增加 32%、术后住院时间延长 45%、出院回家的几率降低 36%和死亡几率增加 2.2 倍有关。
我们证明了在接受术后阿片类药物治疗的先前无阿片类药物使用史的患者中,潜在的 ORADE 发生率高且后果严重。对 ORADE 风险因素和预测因素的了解可以帮助制定有针对性的干预措施,以最大程度地减少这些潜在危险和昂贵事件的发生。